Kidney Week

Oral Abstract Session

IgA Nephropathy: New Therapies and Insights

October 25, 2024 | 04:30 PM - 06:00 PM

Location: Room 6D, Convention Center

Session Description

Oral Abstract Session

Learning Pathway(s)

• Glomerular Diseases

Moderators

• Shikha Wadhwani, MD, MS, FASN
• Dia Rose Waguespack, MD, FASN

Presentations

• Optimizing IgAN Treatment: Comparing Prednisone and Budesonide Efficacy and Safety
  04:30 PM - 04:40 PM
  
  • Abhi Lohana, MD

Optimizing IgAN Treatment: Comparing Prednisone and Budesonide Efficacy and Safety

October 25, 2024 | 04:30 PM - 04:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• NeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial
  04:40 PM - 04:50 PM
  
  • Richard A. Lafayette, MD

NeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial

October 25, 2024 | 04:40 PM - 04:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• PROTECT Subgroup Analysis: Clinical Benefits of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with IgAN Who Have Proteinuria above and below 1 g/g
  04:50 PM - 05:00 PM
  
  • Laura Kooienga, MD

PROTECT Subgroup Analysis: Clinical Benefits of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with IgAN Who Have Proteinuria above and below 1 g/g

October 25, 2024 | 04:50 PM - 05:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Immunodeposits and Urinary Complement Activation Fragments Are Linked to IgAN Activity and Progression: Findings from the CureGN Study
  05:00 PM - 05:10 PM
  
  • Virginie Royal, MD

Immunodeposits and Urinary Complement Activation Fragments Are Linked to IgAN Activity and Progression: Findings from the CureGN Study

October 25, 2024 | 05:00 PM - 05:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial
  05:10 PM - 05:20 PM
  
  • James A. Tumlin, MD, FASN

Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial

October 25, 2024 | 05:10 PM - 05:20 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study
  05:20 PM - 05:30 PM
  
  • Dana V. Rizk, MD

Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study

October 25, 2024 | 05:20 PM - 05:30 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• ALIGN Subgroup Analyses: Clinically Meaningful Urinary Protein-to-Creatinine Ratio Reductions across Subgroups
  05:30 PM - 05:40 PM
  
  • Hiddo Jan L. Heerspink, PhD

ALIGN Subgroup Analyses: Clinically Meaningful Urinary Protein-to-Creatinine Ratio Reductions across Subgroups

October 25, 2024 | 05:30 PM - 05:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Sparsentan (SPAR) as First-Line Treatment of Incident Patients with IgA Nephropathy: Interim Analysis of the SPARTAN Trial
  05:40 PM - 05:50 PM
  
  • Chee Kay Cheung, MBChB, PhD

Sparsentan (SPAR) as First-Line Treatment of Incident Patients with IgA Nephropathy: Interim Analysis of the SPARTAN Trial

October 25, 2024 | 05:40 PM - 05:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• The Anti-APRIL Antibody Sibeprenlimab Reduces Circulating Immune Complexes in Patients with IgAN: The Phase 2 ENVISION Randomized Controlled Trial
  05:50 PM - 06:00 PM
  
  • Jonathan Barratt, MBChB, PhD

The Anti-APRIL Antibody Sibeprenlimab Reduces Circulating Immune Complexes in Patients with IgAN: The Phase 2 ENVISION Randomized Controlled Trial

October 25, 2024 | 05:50 PM - 06:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.